Day: November 3, 2021

I found the field of Oncology very interesting. Saw the article Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients published in 2020. Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, Reprint Addresses Buchler, T (corresponding author), Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic.; Buchler, T (corresponding author), Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic.. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or concate me.. Safety of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Category: pyrazoles-derivatives. In 2020 CANCER MANAG RES published article about CLINICAL-PRACTICE; SURVIVAL; MULTICENTER; ANTITUMOR; SAFETY; SITE; SEX in [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Fac Med 1, Dept Oncol, Videnska 800, Prague 14059, Czech Republic; [Novakova-Jiresova, Alena; Boublikova, Ludmila; Buchler, Tomas] Charles Univ Prague, Thomayer Hosp, Videnska 800, Prague 14059, Czech Republic; [Kopeckova, Katerina; Batko, Stanislav; Linke, Zdenek; Prausov, Jana] Charles Univ Prague, Univ Hosp Motol, Dept Oncol, Prague, Czech Republic; [Chloupkov, Renata] Masaryk Univ, Fac Med, Inst Biostat & Anal, Brno, Czech Republic; [Melichar, Bohuslav] Palacky Univ Med, Dept Oncol, Olomouc, Czech Republic; [Melichar, Bohuslav] Teaching Hosp, Olomouc, Czech Republic; [Petruzelka, Lubos] Charles Univ Prague, Gen Fac Hosp, Dept Oncol, Prague, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Med Sch, Dept Oncol & Radiotherapy, Plzen, Czech Republic; [Finek, Jindrich; Fiala, Ondrej] Charles Univ Prague, Univ Hosp Pilsen, Plzen, Czech Republic; [Fiala, Ondrej] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen, Czech Republic; [Grell, Peter; Kiss, Igor] Masaryk Mem Canc Inst, Dept Comprehens Canc Care, Brno, Czech Republic in 2020, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Purpose: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry. Methods: The CORECT registry, the Czech non-interventional database of patients with mCRC treated with targeted agents, searched for patients with metastatic CRC treated with regorafenib. In total, 555 evaluable patients were identified. Results: The median age at diagnosis was 61.7 years. All patients had disease progression on or after previous systemic treatment. Most patients were treated with an initial dose of 160 mg daily (n = 463; 83.6%). The median duration of treatment was 2.7 months (range 0.023.4 months). By the data cut-off date, 472 patients (85%) had completed treatment with regorafenib and were evaluable for treatment response evaluation. Partial response was reported in 13 patients (2.8%) and disease stabilization in 130 patients (27.5%). Median progression-free survival (PFS) and overall survival (OS) were 3.5 months (95% confidence interval [CI] 3.2-3.7 months) and 9.3 months (95% CI 8.3-10.3 months), respectively. The 6-month OS rate was 67.7% (95% CI 63.4-72.1%). Multivariable analysis showed that female gender, longer interval from diagnosis of metastatic disease, MO stage at diagnosis, and Eastern Cooperative Oncology Group performance status (ECOG PS) 0 were associated with longer PFS, while higher body-mass index (BMI), longer interval from diagnosis of metastatic disease, and ECOG PS of 0 were associated with longer OS. Conclusion: OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Category: pyrazoles-derivatives. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Novakova-Jiresova, A; Kopeckova, K; Boublikova, L; Chloupkov, R; Melichar, B; Petruzelka, L; Finek, J; Fiala, O; Grell, P; Batko, S; Linke, Z; Kiss, I; Prausov, J; Buchler, T or concate me.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Authors Rajakannu, P; Kaleeswaran, D; Banerjee, S; Butcher, RJ; Murugavel, R in ELSEVIER SCIENCE SA published article about SECONDARY BUILDING UNITS; X-RAY STRUCTURES; CRYSTAL-STRUCTURE; PADDLE-WHEEL; MAGNETIC-PROPERTIES; SPECTRAL CHARACTERIZATION; COMPLEXES; COPPER(II); 1,10-PHENANTHROLINE; SOLIDS in [Rajakannu, Palanisamy; Kaleeswaran, Dhananjayan; Banerjee, Subarna; Murugavel, Ramaswamy] Indian Inst Technol, Dept Chem, Bombay 400017, Maharashtra, India; [Butcher, Ray J.] Howard Univ, Dept Chem, Washington, DC 20059 USA in 2019.0, Cited 68.0. Name: 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6

Structural modulation of transition metal carboxylates has been studied by employing different auxiliary ligands in the reactions of metal acetates with substituted benzoic acids. A series of neutral transition metal benzoates [Cu(tbba)(2)(imH)(2)] (1), [Cu(tipba)(2)(2,4,6-collidine)(2)] (2), [Co(tbba)(2) (dmpH)(2)] (3), [Co(tipba)(2)(imH)(2)] (4), [M (tmba)(2)(pymeH)(2)] (M = Cu (5), Co (6) and Zn (7)), [Zn(tmba)(2)(pydmeH(2))] (8), [Cu-2(tmba)(2)(pydmeH(2))(2)] [(tmba)(2)(tmbaH)(2)] (9) and [Zn-2(dmp)(2) (tbba)(2)(dmpH)(2)] (10) have been isolated as products from the reaction between the respective metal acetates and substituted benzoic acids (acids used: 4-tert-butylbenzoic acid (tbbaH), 2,4,6-triisopropylbenzoic acid (tipbaH), 2,4,6-trimethylbenzoic acid (tmbaH)) and N-donor auxiliary ligands (imidazole (imH), 3,5-dimethylpyrazole (dmpH), 2,4,6-collidine, 2-pyridinemethanol (pymeH), and pyridine-2,6-dimethanol (pydmeH(2))). The new complexes have been characterized by both analytical and spectroscopic methods. The molecular structures of 1-10 have further been established by single crystal X-ray diffraction studies. The complexes 1-8 are mononuclear, while compounds 9 and 10 have been found to be dinuclear due to the role of benzoic acid in 9 and pyrazolate anion as bridging ligand in 10. The geometry around the metal ion is square-planar in 1 and 2, tetrahedral in 3, 4 and 10, octahedral in 5-7 and 9 and trigonal-bipyramidal in 8. Complexes with ligands that contain additional functional groups such as > NH and -OH are involved in hydrogen bonding interactions. These weak interactions lead to the formation of 1-D linear polymers or 2-D sheets.

About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Rajakannu, P; Kaleeswaran, D; Banerjee, S; Butcher, RJ; Murugavel, R or concate me.. Name: 3,5-Dimethyl-1H-pyrazole

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

An article Solubility of solid intermediate of pharmaceutical compounds in pure organic solvents using semi-empirical models WOS:000507620300035 published article about MAGNESIUM-DL-ASPARTATE; P-TOLUIC ACID; MIXING PROPERTIES; ACTIVITY-COEFFICIENT; NRTL-SAC; 313.15 K; PREDICTION; INGREDIENTS; PARAMETERS in [Akbari, Falamarz] Eram Inst Higher Educ, Dept Chem, POB 71957-46733, Shiraz, Iran; [Didehban, Khadijeh; Farhang, Mona] Payame Noor Univ, Dept Chem, POB 19395-3697, Tehran, Iran in 2020, Cited 35. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0. Recommanded Product: 86-92-0

A new semi-theoretical equation is suggested for correlation of solid-liquid solubility data with temperature. The (solid + liquid) equilibrium for Terephthaldialdehyde, 4-Nitro-o-phennylenediamine, 2,4-dihydro- 5-methyl-2(4-methylphenyl)-3H-pyrazol-3-one (also named 1-(p-toly1)-3-methyl-5pyrazolone (PTMP)), 2-Amino-5-methylthiazole and 5-chloro-1-methyl-4-nitroimidazole in 18 solvents is correlated with semi-empirical models at temperatures T = 273.15 – 318.15 K under a pressure of 101.2 kPa. Moreover, a modified Apelblat model, lambda h model, Wilson model, NRTL model, new flexible equation as Akbari, Dideban and Farhang model (ADF) and for first time the modified Scatchard-Hildebrand equation were utilized to calculate the experiment values. The performance of both ADF and modified Scatchard-Hildebrand equation have been checked by calculating the solubility data with the AARD% of 1.3808% (for 775 data points) and 0.65% (for 100 data points), respectively. The Wilson model is applied to estimate the mixing Gibbs energy, mixing enthalpy, mixing entropy, activity coefficient (ln gamma(infinity)(1)) and reduced excess enthalpy (H-I(E,infinity)) at infinitesimal concentration were calculated.

Recommanded Product: 86-92-0. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Akbari, F; Didehban, K; Farhang, M or concate me.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Regioselectivity Switch in Palladium-Catalyzed Allenylic Cycloadditions of Allenic Esters: [4+1] or [4+3] Cycloaddition/Cross-Coupling WOS:000462622700046 published article about ASYMMETRIC-SYNTHESIS; SPIROPYRAZOLONES; ISOXAZOLINONES; DENDRALENES; ANNULATION; GENERATION; REACTIVITY; YLIDES in [Li, Long; Luo, Pengfei; Deng, Yuhua; Shao, Zhihui] Yunnan Univ, Key Lab Med Chem Nat Resource, State Key Lab Conservat & Utilizat Bioresources Y, Minist Educ,Sch Chem Sci & Technol, Kunming 650091, Yunnan, Peoples R China in 2019, Cited 65. Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0

The first Pd-catalyzed asymmetric allenylic [4+1] cycloaddition was successfully developed. Alternatively, tuning the Pd catalyst switched the reactivity toward an unprecedented [4+3] cycloaddition/cross-coupling. Ligands play a vital role in controlling the reaction pathway, allowing highly selective access to different products from identical substrates. Biological evaluation of the obtained compounds led to the discovery of new antitumor targets. A possible mechanism is proposed, suggesting two interesting catalytic cycles for the cycloaddition with palladium-butadienyls. This study also demonstrated the potential and utility of allenic esters as 1,4-biselectrophiles and C-4 synthons for participating in cycloaddition reactions.

About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Li, L; Luo, PF; Deng, YH; Shao, ZH or concate me.. Recommanded Product: 3-Methyl-1-p-tolyl-5-pyrazolone

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Shang, JF; Liu, QX; Wang, BL; Li, ZM in [Shang, Junfeng; Liu, Qiaoxia; Wang, Baolei; Li, Zhengming] Nankai Univ, Coll Chem, State Key Lab Elementoorgan Chem, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300071, Peoples R China published Synthesis and Biological Activities of Novel N-Substitutedphenyl-2-pyrazolylnicotinamides in 2019.0, Cited 18.0. Safety of 3,5-Dimethyl-1H-pyrazole. The Name is 3,5-Dimethyl-1H-pyrazole. Through research, I have a further understanding and discovery of 67-51-6.

Based on the agrochemical structure of anthranilic diamides, fourteen novel N-substittitedphenyl-2-pyrazolylnicotinamides were conveniently synthesized with 2-chloro-3-cyanopyridine and 4-bromopyrazole or 3,5-dimethylpyrazole as starting materials, via an acyl transposing design strategy. Their structures were characterized by 1H NMR, 13C NMR and HRMS. The preliminary bioassay tests indicated that most of these compounds exhibited obvious insecticidal activity at the test concentration of 200 mg/L, among which N-(4-chloro-2-(ethylcarbamoyl)-6-methylphenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)nicotinamide (II) possessed a 70% mortality rate against Mythimna separata Walker: some of the compounds displayed favorable fungicidal activities at 50 mg/L towards Physalospora piricola and Alternaria solani Sorauer, especially 2-(4-bromo-1H-pyrazol-1-yl)-N-(2-(cyclopropylcarbamoyl)-4-iodo-6-methylphenyl)nicotinamide (If) and 2-(4-bromo-1H-pyrazol-1-yl)-N-(4-chloro-2-(ethylcarbamoyl)-6-methylphenyl)nicotinamide (Ih) against Physalospora piricola, and 2-(4-bromo-1H-pyrazol-1-yl)-N-(4-chloro-2-(propylcarbamoyl)phenyl)nicotinamide (Id) against Alternaria solani Sorauer had growth inhibitory rates of 62.9%, 54.3% and 54.5%, respectively. These research results provide important reference for the further study of novel 2-pyrazolylnicotinamide derivatives.

Safety of 3,5-Dimethyl-1H-pyrazole. About 3,5-Dimethyl-1H-pyrazole, If you have any questions, you can contact Shang, JF; Liu, QX; Wang, BL; Li, ZM or concate me.

Reference:
Pyrazole – Wikipedia,
,Pyrazoles – an overview | ScienceDirect Topics

I found the field of Acoustics; Radiology, Nuclear Medicine & Medical Imaging very interesting. Saw the article A real-time data-based scan conversion method for single element ultrasound transducers published in 2019. SDS of cas: 83-10-3, Reprint Addresses Csany, G (corresponding author), Pazmany Peter Catholic Univ, Fac Informat Technol & Bion, Budapest, Hungary.. The CAS is 83-10-3. Through research, I have a further understanding and discovery of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

The current work investigates the performance of a real-time scan conversion algorithm for generating a 2-D ultrasound image from a laterally scanned single-element ultrasound transducer, which has applications in point-of-care devices such as for skin imaging. The algorithm employs a fixed calibration curve to update a predefined image grid in real time. Simulations showed that the calibration curve (with a maximum of 1) is robust to changes in scatterer concentration (8.3 x 10(-3) mean absolute error), signal to noise ratio (1.0 x 10(-3) mean absolute error for -5 dB SNR), and can be accurately predicted from a small number (31) of point scatterers (6.9 x 10(-3) mean absolute error). Good agreement was also found between the calibration curves obtained from simulated and experimental data (1.19 x 10(-2) mean absolute error). The scan conversion algorithm was validated by evaluation of the position estimation errors on both simulations and experiments. Clinical images of skin lesions (N = 20) demonstrate the feasibility of the algorithm for real, non-homogeneous tissue. Use of a fixed calibration curve compared to an adaptive calibration curve gave similar accuracies in the scanning step size range of 150-350 mu m (with an average overlap of the accuracy ranges of 92.94% for simulations and 42.83% for experiments), and a 350-fold improvement in computation time.

About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Csany, G; Szalai, K; Gyongy, M or concate me.. SDS of cas: 83-10-3

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

HPLC of Formula: C12H12N2O3. In 2021 AGE AGEING published article about DRUG-REACTIONS; MEDICATION USE; OLDER-PEOPLE; CARE; COMORBIDITIES in [Delgado, Joao; Jones, Lindsay; Ballard, Clive; Melzer, David] Univ Exeter, Coll Med & Hlth, Epidemiol & Publ Hlth, Exeter EX1 2LU, Devon, England; [Bradley, Marie C.] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA; [Allan, Louise M.; Clare, Linda] Univ Exeter, Coll Med & Hlth, Ctr Res Ageing & Cognit Hlth, Exeter EX1 2LU, Devon, England; [Fortinsky, Richard H.] Univ Connecticut, Sch Med, Ctr Aging, Mansfield, CT 06030 USA; [Hughes, Carmel M.] Queens Univ Belfast, Med Biol Ctr, Sch Pharm, Belfast BT9 7BL, Antrim, North Ireland in 2021, Cited 30. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3.

Importance: treatment of dementia in individuals with comorbidities is complex, leading to potentially inappropriate prescribing (PIP). The impact of PIP in this population is unknown. Objective: to estimate the rate of PIP and its effect on adverse health outcomes (AHO). Design: retrospective cohort. Setting: primary care electronic health records linked to hospital discharge data from England. Subjects: 11,175 individuals with dementia aged over 65 years in 2016 and 43,463 age- and sex-matched controls. Methods: Screening Tool of Older Persons’ Prescriptions V2 defined PIP. Logistic regression tested associations with comorbidities at baseline, and survival analyses risk of incident AHO, adjusted for age, gender, deprivation and 14 comorbidities. Results: the dementia group had increased risk of PIP (73% prevalence; odds ratio [OR]: 1.92; confidence interval [CI]: 83-103%; P < 0.01) after adjusting for comorbidities. Most frequent PIP criteria were related to anti-cholinergic drugs and therapeutic duplication. Risk of PIP was higher in patients also diagnosed with coronary-heart disease (odds OR: 2.17; CI: 1.91-2.46; P < 0.01), severe mental illness (OR: 2.09; CI: 1.62-2.70; P < 0.01); and depression (OR: 1.81; CI: 1.62-2.01; P < 0.01). During follow-up (1 year), PIP was associated with increased all-cause mortality (hazard ratio: 1.14; CI: 1.021.26; P < 0.02), skin ulcer and pressure sores (hazard ratio: 1.66; CI: 1.12-2.46; P< 0.01), falls (hazard ratio: 1.37; CI: 1.15-1.63; P < 0.01), anaemia (hazard ratio: 1.61; CI: 1.10-2.38; P < 0.02) and osteoporosis (hazard ratio: 1.62; CI: 1.022.57; P < 0.04). Conclusion: patients with dementia frequently receive PIPs, and those who do are more likely to experience AHO. These results highlight the need to optimise medication in dementia patients, especially those with comorbidities. HPLC of Formula: C12H12N2O3. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Delgado, J; Jones, L; Bradley, MC; Allan, LM; Ballard, C; Clare, L; Fortinsky, RH; Hughes, CM; Melzer, D or concate me.

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

Authors Zhou, L; Yan, JX; Huang, JL; Wang, HB; Wang, XG; Wang, ZJ in ELSEVIER SCI LTD published article about in [Zhou, Liang; Yan, Junxiao; Huang, Julong; Wang, Hongbo; Wang, Xingang; Wang, Zhenjun] Changan Univ, Sch Mat Sci & Engn, Xian 710064, Peoples R China; [Zhou, Liang; Wang, Hongbo; Wang, Xingang; Wang, Zhenjun] Changan Univ, Minist Educ, Engn Res Ctr Transportat Mat, Xian 710061, Peoples R China in 2021, Cited 46. Application In Synthesis of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. The Name is 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid. Through research, I have a further understanding and discovery of 83-10-3

Here in, the effects of FeSiAl particle size on the dielectric and microwave absorption properties of FeSiAl/Al2O3 composites were studied. FeSiAl/Al2O3 composites containing 18-25 mu m, 25-48 mu m, and 48-75 mu m FeSiAl particles were prepared by hot-pressed sintering based on uniformly mixed FeSiAl and Al2O3 powders. Results show that the real permittivity and the imaginary permittivity are significantly promoted with increasing FeSiAl particle size, which is ascribed to the enhanced interfacial polarization and conductance loss. In addition, the favorable matching impedance and suitable attenuation coefficient enabled the composite containing 25-48 mu m FeSiAl powder to show a minimum reflection loss of -34.4 dB at 11.7 GHz and an effective absorption bandwidth (<-10 dB) of 1.4 GHz in 11.0-12.4 GHz, when the thickness is 1.1 mm. By adjusting the thickness to 1.4 mm, the effective absorption bandwidth of the composite reaches a maximum value of 2.0 GHz in the 8.3-10.3 GHz range, indicating tunable, strong, and highly efficient microwave absorption performance. About 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid, If you have any questions, you can contact Zhou, L; Yan, JX; Huang, JL; Wang, HB; Wang, XG; Wang, ZJ or concate me.. Application In Synthesis of 1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxylic acid

Reference:
Patent; Shanghai Pharmaceutical Industry Institute; China Pharmaceutical Industry Zongyuan; Li Jianqi; Huang Daowei; Wang Wenya; Zhang Zhiguo; Jiang Ling; (45 pag.)CN107286140; (2017); A;,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics

An article Asymmetric Organocatalysis Combined with Palladium Catalysis: Synergistic Effect on Enantioselective Mannich/alpha-Allylation Sequential Reactions of Pyrazolones in Constructing Vicinal Quaternary Stereocenters WOS:000489200100005 published article about ALLYLIC DEAROMATIZATION REACTION; STEREOCONTROLLED CONSTRUCTION; MICHAEL ADDITION; ALKYLATION; ACID; PYRAZOLIN-5-ONES; PYRAZOL-5-ONES; ALCOHOLS; BEARING in [Wu, Gengxin; Xu, Haohan; Liu, Ziran; Liu, Yonghong; Yang, Xiang; Huang, Yan] Xinjiang Univ, Coll Chem & Chem Engn, Key Lab Oil & Gas Fine Chem, Minist Educ & Xinjiang Uyghur Autonomous Reg, Urumqi 830000, Xinjiang, Peoples R China; [Zhang, Xulong] Xinjiang Uygur Autonomous Reg Prod Qual Supervis, Urumqi 830000, Xinjiang, Peoples R China in 2019, Cited 46. HPLC of Formula: C11H12N2O. The Name is 3-Methyl-1-p-tolyl-5-pyrazolone. Through research, I have a further understanding and discovery of 86-92-0

In this letter, an efficient one-pot asymmetric sequential reaction is achieved by organo/transition metal relay catalysis in constructing two consecutive C-C bonds, which involves enantioselective amino squaramide catalytic Mannich-type addition of pyrazolones to isatin-derived ketimines and a subsequent palladium catalyzed diastereoselective allylic alkylation of pyrazolones with allylic acetates. An array of novel pyrazolone-aminooxindole-propylene structural motifs are obtained in a high level of yield and with excellent enantio- and diastereoselectivity (up to 95% yield, >20:1 dr, >99% ee). This methodology features the formation of vicinal quarternary carbon-stereocenters, and the second all-carbon tetrasubstituted stereogenic center is induced by joint action of the achiral palladium catalysis and the chiral environment generated from the Mannich step. Moreover, the usefulness of this methodology is highlighted by converting the allylic product into the carbonyl compound.

HPLC of Formula: C11H12N2O. About 3-Methyl-1-p-tolyl-5-pyrazolone, If you have any questions, you can contact Wu, GX; Xu, HH; Liu, ZR; Liu, YH; Yang, X; Zhang, XL; Huang, Y or concate me.

Reference:
Article; Zhang, Yong; Nie, Long-Jun; Luo, Liang; Mao, Jia-Xin; Liu, Jin-Xiang; Xu, Guo-Hai; Chen, Deliang; Luo, Hai-Qing; Tetrahedron; vol. 76; 7; (2020);,
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics